SecBot SecBot
PRESS-RELEASE ·Filed Apr 30, 2026

EBS

Emergent BioSolutions
MIXED
Impact 6/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

The EPS beat and raised adjusted EBITDA/adjusted net income guidance are positive, but the 30% revenue decline and unchanged top-line guidance signal ongoing structural headwinds in MCM product sales. Monitor Q2 2026 revenue forecast of $170-$185M and the trajectory of Naloxone and MCM contract renewals.

DirectionMixed
Confidencehigh
Horizonweeks

Drugs in focus

EBS drug pipeline →

ACAM2000

● Neutral Named in this press release
Impact
Phase
Approved
Time to market
Already approved and marketed since 2007 (smallpox) and 2024 (mpox).
Next catalyst
None dated

What to watchACAM2000 is an approved, revenue-generating product with no pending FDA binary catalyst. Watch for U.S. government contract option exercises (the 10-year ASPR deal has annual renewals) and further international approvals, which drive lumpy quarterly revenue. The Q3 2026 revenue miss and lowered guidance are the near-term headwind to watch.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$8.47
T+0 close · Apr 30, 2026 · via day close
Latest settled
−13.70%
T+60 · $7.31
Vs SPY
−16.76%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 1 $8.47entry
  2. T+1 · 7mo ago +0.83%α +1.17% · $8.54
  3. T+5 · 6mo ago +7.79%α +5.45% · $9.13
  4. T+20 · 6mo ago +0.24%α −5.05% · $8.49
  5. T+60 · 4mo ago −13.70%α −16.76% · $7.31
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Emergent BioSolutions reported Q1 2026 adjusted net income per diluted share of $0.21, beating the consensus estimate of -$0.25, but total revenues fell 30% YoY to $156.1M, below the $160.5M consensus. The company raised its full-year 2026 adjusted EBITDA guidance to $155-$175M (from $135-$155M) and adjusted net income guidance to $45-$65M (from $25-$45M), while keeping revenue guidance unchanged at $720-$760M.

Key Financial Metrics

EPS (Adj.)
$0.21
est −$0.25 · +184.0% · GAAP: $0.07
Revenue
$156.1M
est $160.5M · -2.7% · -29.7% YoY
Rating
in line
Guidance
$720M-$760M
raised
Free Cash Flow
-$36.2M
Gross Margin
41%

Key Facts

  • Q1 2026 total revenues of $156.1M, down 30% YoY from $222.2M
  • Q1 2026 GAAP net income of $6.8M ($0.07 diluted EPS), down 90% from $68.0M ($1.19 diluted EPS)
  • Adjusted net income per diluted share of $0.21, beating consensus of -$0.25
  • Adjusted EBITDA of $35.6M, down 55% from $79.1M YoY
  • Full-year 2026 revenue guidance unchanged at $720-$760M
  • Full-year 2026 adjusted EBITDA guidance raised to $155-$175M from $135-$155M
  • Full-year 2026 adjusted net income guidance raised to $45-$65M from $25-$45M
  • Smallpox MCM revenue fell 40% to $64.2M; Anthrax MCM revenue fell 55% to $21.6M
  • Naloxone revenue fell 5% to $42.9M
  • Board authorized up to $50M in share repurchases through March 2027
  • Debt refinancing with new $150M term loan facility completed in April 2026

Financial Impact

Revenue decline of $66.1M YoY (30%); adjusted EBITDA guidance raised by $20M at midpoint

revenuenet incomeadjusted EBITDAadjusted net income

Segment Breakdown

SegmentRevenueGrowth
Commercial Products$42.9M-5.3%
MCM Products$101.8M-35.0%

Risk Factors

  • Sustained revenue decline driven by lower MCM product sales to US and international governments
  • Dependence on government procurement contracts with uncertain timing and funding
  • High debt load ($573.6M) and interest expense ($11M in Q1) despite refinancing
  • Negative operating cash flow of -$33.8M in Q1 2026

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3285513

Track record

23 reports on EBS

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +14.89% at T+20 after the Apr 29, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today Institutional Cluster Neutral 3/10 Entry $5.76 Now $5.81 +0.96% settles Nov 23
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $5.75 Now $5.81 +1.13% settles Nov 23
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $5.79 Now $5.81 +0.35% settles Nov 23
  4. Nov 4, 202612d ago 8-K Neutral 4/10 Entry $5.85 to $5.89 Now $5.81 −0.68% ▲ +0.68% −2.61% vs SPY
  5. Nov 2, 202614d ago 8-K Bearish 6/10 Entry $6.25 to $6.05 Now $5.81 +7.04% ▲ +3.20% +2.61% vs SPY
  6. Oct 30, 202617d ago Institutional Cluster Neutral 2/10 Entry $6.81 to $6.06 Now $5.81 −14.68% ▼ −11.01% −8.31% vs SPY
  7. Oct 16, 20264w ago 8-K Neutral 3/10 Entry $6.38 to $6.23 Now $5.81 −8.93% ▼ −2.35% −2.44% vs SPY
  8. Oct 7, 20265w ago 144 Neutral 2/10 Entry $6.81 to $7.18 Now $5.81 −14.68% ▲ +5.43% +5.71% vs SPY
  9. Jun 29, 202620w ago 8-K Bullish 5/10 Entry $8.46 to $8.18 Now $5.81 −31.32% ▼ −3.31% −4.70% vs SPY
  10. Jun 4, 202623w ago Press Release Neutral 2/10 Entry $8.44 to $8.39 Now $5.81 −31.16% ▼ −0.59% +1.96% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 30, 2026